-
Ipilimumab, sold
under the
brand name Yervoy, is a
monoclonal antibody medication that
works to
activate the
immune system by
targeting CTLA-4, a protein...
- first-line
treatment for
inoperable or
metastatic melanoma in
combination with
ipilimumab if the
cancer does not have a
mutation in BRAF, and as a second-line treatment...
-
group using the vaccine, 44% in the
vaccine and
ipilimumab group, and 46% in the
group treated with
ipilimumab alone. However, some have
raised concerns about...
- function. The
first anti-cancer drug
targeting an
immune checkpoint was
ipilimumab, a CTLA4
blocker approved in the
United States in 2011.
Currently approved...
-
immune function.
Approved checkpoint inhibitors include antibodies such as
ipilimumab, nivolumab, and pembrolizumab.
Dendritic cell
therapy provokes anti-tumor...
-
Treatment with pembrolizumab, atezolizumab, or
combination nivolumab plus
ipilimumab are all
superior to
chemotherapy alone against tumors expressing PD-L1...
- Program. It is
approved for use
following treatment with
ipilimumab, or
after treatment with
ipilimumab and a BRAF
inhibitor in
advanced melanoma patients who...
-
response to
ipilimumab. The
Phase III
clinical failure of Pfizer's
tremelimumab anti-CTLA-4
monoclonal antibody,
which competed with
ipilimumab, provided...
-
combination with
ipilimumab demonstrating an ORR of 44% in
melanoma patients refractory to anti-PD1
therapy vs 10-13%
response rate with
ipilimumab monotherapy...
-
patients with
melanoma in
combination with the
immune checkpoint inhibitor ipilimumab and the BRAF (gene)
inhibitor vemurafenib. The
following table, summarizing...
